Search or filter publications

Filter by type:

Filter by publication type

Filter by year:

to

Results

  • Showing results for:
  • Reset all filters

Search results

  • Journal article
    Griesenbach U, Jeswiet SB, Larsen MD, Bakar Y, Voase NW, Gammie F, Gray RD, Horsley A, Imrie M, Dewar M, Marriott C, Geddes DM, Davies JC, Alton EWet al., 2007,

    UKCF gene therapy consortium tracking study: Change in sputum properties in response to IV antibiotic

    , PEDIATRIC PULMONOLOGY, Pages: 229-229, ISSN: 8755-6863
  • Journal article
    Horsley A, Macleod K, Saunders C, Gray RD, Dewar M, Voase N, Porteous D, Boyd C, Hyde S, Gill D, Geddes D, Greening AP, Cunningham S, Davies JC, Alton E, Innes JAet al., 2007,

    UKCF gene therapy consortium tracking study: Lung clearance index improves with treatment of an infective exacerbation

    , PEDIATRIC PULMONOLOGY, Pages: 335-336, ISSN: 8755-6863
  • Journal article
    Davies J, Voase N, Dewar M, Mullard K, Gammie F, Saunders C, Horsley A, Gray R, MacLeod K, Somerton L, Higgins T, Donovan T, Cornish N, Hansell D, Aziz Z, Ashby D, Geddes D, Greening A, Cunningham S, Innes A, Alton Eet al., 2007,

    UKCF Gene Therapy Consortium tracking study: Response of clinically-available assays to intravenous antibiotics

    , PEDIATRIC PULMONOLOGY, Pages: 347-347, ISSN: 8755-6863
  • Journal article
    Verdejo R, Lamoriniere S, Cottam B, Bismarck A, Shaffer Met al., 2007,

    Removal of oxidation debris from multi-walled carbon nanotubes

    , CHEMICAL COMMUNICATIONS, Pages: 513-515, ISSN: 1359-7345
  • Book chapter
    Alton EWFW, Davies JC, Geddes DM, 2006,

    Gene therapy for lung diseases

    , Principles of Molecular Medicine, Pages: 259-268

    Gene therapy is under development for a variety of lung disease, both those caused by single gene defects, such as cystic fibrosis and α<inf>1</inf>- antitrypsin deficiency, and multifactorial diseases such as cancer, asthma, lung fibrosis, and ARDS. Both viral and nonviral approaches have been explored, the major limitation to the former being the inability to repeatedly administer, which renders this approach perhaps more applicable to conditions requiring single administration, such as cancer. Progress in development and clinical trials in each of these diseases is reviewed, together with some potential newer approaches for the future. © 2006 Humana Press Inc.
  • Journal article
    Pommet M, Juntaro J, Bismarck A, 2006,

    Natural fibre reinforced cellulose nanocomposites

    , Aiche Annual Meeting Conference Proceedings
  • Conference paper
    Wort SJ, McMaster S, Mitchell JA, Evans TW, Ito M, Ito K, Adcock IMet al., 2006,

    Acetylation of histone H4 at NF-ΚB sites on pre-pro ET-1 promoter is involved in synergistic synthesis of ET-1 in human pulmonary artery smooth muscle cells treated with TNF-α and IFN-γ

    , Winter Meeting of the British-Thoracic-Society/British-Lung-Foundation (BTS/BLF), Publisher: B M J PUBLISHING GROUP, Pages: II19-II19, ISSN: 0040-6376
  • Journal article
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RMet al., 2006,

    A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

    , ARTHRITIS AND RHEUMATISM, Vol: 54, Pages: 3962-3970, ISSN: 0004-3591
  • Journal article
    Spratt BG, Staley JT, Fisher MC, 2006,

    Introduction: species and speciation in micro-organisms

    , PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, Vol: 361, Pages: 1897-1898, ISSN: 0962-8436
  • Journal article
    Caramori G, Ito K, Papi A, Adcock IMet al., 2006,

    Interactions between long-acting β2-agonists and glucocorticoids

    , Drug Discovery Today Therapeutic Strategies, Vol: 3, Pages: 261-268, ISSN: 1740-6773

    Long acting β<inf>2</inf>-agonists and glucocorticoids together control asthma in ∼95% of affected individuals, although symptoms return after treatment is stopped. Treatment of chronic obstructive pulmonary disease (COPD) scarcely influences the natural course of the disease. Neither long-acting β<inf>2</inf>-agonists (LABAs) nor glucocorticoids alone significantly influence the course of COPD. Recent evidence suggests that a combination of the two therapies is more promising: It can decrease the exacerbation rates in severe COPD and may also decrease mortality. © 2006 Elsevier Ltd. All rights reserved.

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://www.imperial.ac.uk:80/respub/WEB-INF/jsp/search-t4-html.jsp Request URI: /respub/WEB-INF/jsp/search-t4-html.jsp Query String: id=1255&limit=10&resgrpMemberPubs=true&resgrpMemberPubs=true&page=415&respub-action=search.html Current Millis: 1783979979597 Current Time: Mon Jul 13 22:59:39 BST 2026

General enquiries

 For any enquiries about the Fungal Science Network at Imperial, please contact:

fungalnetwork@imperial.ac.uk